327 related articles for article (PubMed ID: 19856919)
1. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
[TBL] [Abstract][Full Text] [Related]
2. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
3. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
[TBL] [Abstract][Full Text] [Related]
6. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
7. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
[TBL] [Abstract][Full Text] [Related]
8. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
[TBL] [Abstract][Full Text] [Related]
10. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
[TBL] [Abstract][Full Text] [Related]
13. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO
Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
[TBL] [Abstract][Full Text] [Related]
18. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
[TBL] [Abstract][Full Text] [Related]
20. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
